Moxifloxacin: 4 agencies, 2003–2019
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 15.5 years separate the first record, 18 Aug 2003 at AWMSG (Wales), from the most recent, 6 Feb 2019 at HAS (France).
HAS (France) changed its position: recommended on 21 Jul 2010, not recommended by 6 Feb 2019.
No assessment is on file from PBAC (Australia), TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Nothing has been added since 2019; on this evidence the file is dormant.
3 distinct indication wordings are recorded for moxifloxacin by the agencies that label one in English (AWMSG and SMC).
AWMSG (Wales) was first to assess moxifloxacin, on 18 Aug 2003; PHARMAC (New Zealand) did not open a file until 14 Feb 2013 — an unusually long tail of 9.5 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 8 years in total.
3 of the 4 agencies here assessed moxifloxacin more than once, HAS (France) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed moxifloxacin.
The full ledger for moxifloxacin reads 7 recommended, 2 other, 1 not recommended and 1 restricted, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 6 Feb 2019 | Listing (Transparency Committee) | SMR insufficient · ASMR V | source |
| PHARMAC (New Zealand) | 2 Nov 2017 | Mycoplasma genitalium for azithromycin resistance | PTAC advice: High · decision reached | source |
| PHARMAC (New Zealand) | 11 Feb 2016 | Post-splenectomy, confirmed allergy to penicillin | PTAC advice: Medium · decision reached | source |
| SMC (Scotland) | 13 Dec 2010 | Community Acquired Pneumonia (CAP) | accepted (restricted) | source |
| AWMSG (Wales) | 18 Aug 2003 | Treatment of bacterial infections in patients of 18 years and older caused by bacteria susceptible to moxifloxacin | outside AWMSG criteria | source |
7 further decisions for moxifloxacin, across 3 agencies, are not shown here. They link to 6 further source documents.
Related molecules
- ciprofloxacin — same ATC class J01M — Antibacterials
- levofloxacin — same ATC class J01M — Antibacterials
- teriparatide — also decided by HAS in 2019Q1
- ulipristal — also decided by HAS in 2019Q1
- bimatoprost — also decided by HAS in 2019Q1
- glibenclamide — also decided by HAS in 2019Q1
Coverage: 12 decisions for moxifloxacin from 4 agencies, 2003 to 2019. Data to 7 Sep 2026. ATC class J01M — Antibacterials. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.